Financial Performance - The company achieved a 5.3% year-over-year (YoY) pro forma revenue growth in FY 2024[3] - Q4 FY 2024 pro forma revenue growth was 11.3%[4] - Med Tech segment gross margin reached 63.3% in FY 2024, compared to 47.7% in FY 2023[5] - Net sales for FY 2024 were $270.7 million, a 10.1% pro forma growth compared to FY 2023[5] - Q4 FY 2024 net sales were $71.1 million, compared to $69.8 million in Q4 2023[4] Strategic Initiatives - The company eliminated $50 million of long-term debt and bolstered the balance sheet[3,22] - The company settled a patent litigation suit with C R Bard[3,23] - The company initiated a shift to outsourced manufacturing, expected to generate $15 million in annual cost savings by FY 2027[3,23] - The company is pursuing larger, faster-growing markets, with Med Tech TAM increasing by 233% to $10 billion[6] Product Performance - AlphaVac sales saw a 68% sequential increase in Q4 2024[3,20] - NanoKnife disposables sales for FY 2024 were $18 million, a 16% YoY growth[21] - NanoKnife capital sales for FY 2024 were $6.5 million, a 100% YoY growth[21]

Exhibit 99.1 /namics PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results LATHAM, N.Y.--(BUSINESS WIRE)--Jul. 16, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patient ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | AngioD ...

Financial Data and Key Metrics Changes - The company reported revenue of $66 million for Q3 FY24, representing an 8% year-over-year growth, with med tech segment growth of nearly 13% and med device segment growth of 5% [10][20] - Adjusted net loss for Q3 FY24 was $6.5 million, or adjusted loss per share of $0.16, compared to an adjusted net loss of $5.4 million or adjusted loss per share of $0.14 in the same quarter last year [26] - GAAP net loss for Q3 FY24 was $190.4 million, including a goodwill impairment charge of $159.5 million [27] Business Line Data and Key Metrics Changes - Med tech revenue was $25.7 million, a 12.6% year-over-year increase, while med device revenue was $40.3 million, growing 5.2% compared to Q3 FY23 [20] - Auryon platform contributed $11.8 million in revenue during Q3, growing 14.7% year-over-year [21] - NanoKnife disposable revenue increased 19.8% year-over-year, with capital sales growing 230.9% [22] Market Data and Key Metrics Changes - International business grew approximately 21% year-over-year, with med tech growing 53% and med device growing 7% [16] - The company expects to initiate a limited launch of AlphaVac for pulmonary embolism treatment by the end of Q4 FY24, with a full launch scheduled for Q1 FY25 [12][13] Company Strategy and Development Direction - The company is focused on optimizing its portfolio, having divested its PICC and midline product portfolios for up to $45 million, with $30 million received in Q3 [17] - The transition to a fully outsourced manufacturing model is underway, expected to generate approximately $15 million in annualized savings starting in FY26 [18][24] - The company aims to drive growth from key med tech platforms while expanding margins and moving towards profitability [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy, highlighting the FDA clearance for AlphaVac as a significant milestone [12] - The company anticipates FY24 revenue in the range of $270 million to $275 million, reflecting the impact of recent divestitures [32] - Management noted that there are no significant market changes affecting guidance, maintaining a consistent outlook despite operational transitions [42] Other Important Information - The company has zero debt compared to $50 million a year ago, significantly strengthening its balance sheet [28][30] - A settlement agreement with BD Bard was reached, resolving over a decade of IP litigation, providing clarity and allowing the company to focus on growth [31] Q&A Session Summary Question: When will data from the APEX trial be available? - Management indicated that data will be released at upcoming trade shows and through publications from principal investigators [36] Question: What are the rollout plans for AlphaVac in PE? - The company has prepared its sales force and will conduct a limited market release followed by a larger launch [48] Question: Will there be any changes in guidance due to recent divestitures? - Management confirmed that guidance remains consistent, reflecting the divestiture's impact without significant market changes [42] Question: What is the pricing strategy for AlphaVac? - The expected price for AlphaVac is around $9,000 [60] Question: How is the NanoKnife performing and when will PRESERVE data be available? - The NanoKnife is seeing strong growth, particularly in prostate treatments, with data from the PRESERVE study expected to be published following the 12-month follow-up [62]

Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture Fiscal Year 2024 Third Quarter Highlights • Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 o Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax support ...

[Part I: Financial Information](index=4&type=section&id=Part%20I%3A%20Financial%20Information) [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited consolidated financial statements for the quarterly period ended November 30, 2023 - On June 8, 2023, the company completed the sale of its dialysis and BioSentry businesses for **$100.0 million in cash**, resulting in a pre-tax book gain of **$47.8 million**[37](index=37&type=chunk) - On January 5, 2024, the company announced a plan to shift its New York manufacturing operations to a **fully outsourced model**, expected to be completed in Q3 FY2026[106](index=106&type=chunk) [Consolidated Statements of Operations](index=4&type=section&id=Consolidated%20Statements%20of%20Operations) The company reported a Q2 net loss of $29.0 million, a significant increase from the prior-year period's $8.5 million loss Consolidated Statements of Operations Highlights (unaudited, in thousands) | Metric | Three Months Ended Nov 30, 2023 | Three Months Ended Nov 30, 2022 | Six Months Ended Nov 30, 2023 | Six Months Ended Nov 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | **Net sales** | $79,073 | $85,429 | $157,752 | $166,966 | | **Gross profit** | $40,262 | $45,078 | $80,322 | $87,383 | | **Operating income (loss)** | $(13,120) | $(8,115) | $21,910 | $(21,416) | | **Net income (loss)** | $(29,048) | $(8,486) | $16,836 | $(21,490) | | **Diluted EPS** | $(0.72) | $(0.21) | $0.42 | $(0.55) | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) Total assets decreased to $499.6 million while total liabilities were significantly reduced due to debt extinguishment Balance Sheet Summary (unaudited, in thousands) | Metric | Nov 30, 2023 | May 31, 2023 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $60,896 | $44,620 | | **Total current assets** | $185,468 | $163,542 | | **Total assets** | $499,623 | $532,637 | | **Total current liabilities** | $78,037 | $83,825 | | **Long-term debt** | $0 | $49,818 | | **Total liabilities** | $98,397 | $154,341 | | **Total Stockholders' Equity** | $401,226 | $378,296 | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Investing activities provided $96.6 million from an asset sale, while financing activities used $59.9 million for debt repayment Cash Flow Summary (unaudited, in thousands) | Activity | Six Months Ended Nov 30, 2023 | Six Months Ended Nov 30, 2022 | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(20,633) | $(17,246) | | **Net cash provided by (used in) investing activities** | $96,649 | $(6,072) | | **Net cash (used in) provided by financing activities** | $(59,942) | $24,479 | | **Net increase in cash and cash equivalents** | $16,276 | $1,032 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses a 7.4% revenue decrease in Q2 FY2024, driven by divestitures, and an improved liquidity position [Results of Operations](index=27&type=section&id=Results%20of%20Operations) Q2 FY2024 net sales decreased by $6.4 million year-over-year, primarily due to the impact of business divestitures Net Sales by Segment (in thousands) | Segment | Three Months Ended Nov 30, 2023 | Three Months Ended Nov 30, 2022 | $ Change | | :--- | :--- | :--- | :--- | | Med Tech | $25,363 | $24,502 | $861 | | Med Device | $53,710 | $60,927 | $(7,217) | | **Total** | **$79,073** | **$85,429** | **$(6,356)** | Gross Profit by Segment (in thousands) | Segment | Three Months Ended Nov 30, 2023 | Three Months Ended Nov 30, 2022 | Gross Margin % (2023) | Gross Margin % (2022) | | :--- | :--- | :--- | :--- | :--- | | Med Tech | $15,816 | $15,614 | 62.4% | 63.7% | | Med Device | $24,446 | $29,464 | 45.5% | 48.4% | | **Total** | **$40,262** | **$45,078** | **50.9%** | **52.8%** | - R&D expense **increased by $1.8 million** for the three months ended Nov 30, 2023, primarily due to the timing of projects and clinical spend[129](index=129&type=chunk) - General and administrative expense **decreased by $1.5 million** for the three months ended Nov 30, 2023, driven by lower compensation and benefits expenses[130](index=130&type=chunk) [Liquidity and Capital Resources](index=31&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity strengthened with cash rising to $60.9 million after repaying its entire $50.0 million debt - Cash and cash equivalents totaled **$60.9 million** as of November 30, 2023, an increase from $44.6 million as of May 31, 2023[137](index=137&type=chunk) - The company had **no outstanding debt** as of November 30, 2023, as the Credit Agreement was extinguished in connection with the divestiture[137](index=137&type=chunk) - Key financing activities in the first six months of FY2024 included a **$50.0 million repayment** of the Credit Agreement and a **$10.0 million contingent consideration payment**[141](index=141&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=33&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks include foreign currency fluctuations and a limited concentration of credit risk - The company is exposed to market risk from changes in currency exchange rates, particularly the Euro, British Pound, and Canadian Dollar[146](index=146&type=chunk)[147](index=147&type=chunk) - Concentration of credit risk is limited as **no single customer represents more than 10% of total sales**[149](index=149&type=chunk) [Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of November 30, 2023 - The Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were **effective** as of the end of the period covered by the report[151](index=151&type=chunk) - There were **no material changes** in internal control over financial reporting during the fiscal quarter ended November 30, 2023[152](index=152&type=chunk) [Part II: Other Information](index=35&type=section&id=Part%20II%3A%20Other%20Information) [Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in ongoing patent litigation, but a potential loss is not yet considered probable or estimable - The company is involved in multiple patent infringement lawsuits with C.R. Bard, Inc. regarding its implantable port products, with a jury trial scheduled for April 29, 2024[96](index=96&type=chunk)[97](index=97&type=chunk) - For the ongoing legal proceedings, the company has **not recorded an expense** because a potential loss is not yet probable or reasonably estimable[97](index=97&type=chunk)[98](index=98&type=chunk)[99](index=99&type=chunk) [Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) A key future risk involves the potential need for additional financing for growth, which may not be available on favorable terms - Following the sale of businesses and repayment of debt, the company may require additional financing for future growth, which **may not be available on favorable terms**[157](index=157&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=35&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company repurchased a small number of shares from employees to satisfy tax withholding obligations on vested equity awards Issuer Purchases of Equity Securities (Q2 FY2024) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | Sep 2023 | 0 | $7.26 | | Oct 2023 | 1,802 | $6.81 | | Nov 2023 | 733 | $6.65 | | **Total** | **2,535** | **$6.76** | - The shares were purchased from employees to satisfy tax withholding requirements and **not as part of a publicly announced repurchase program**[159](index=159&type=chunk) [Other Information](index=35&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated a Rule 10b5-1 trading arrangement during the quarter - **No directors or officers adopted or terminated** a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" during the quarter[161](index=161&type=chunk)

Financial Data and Key Metrics Changes - Revenue for Q2 FY 2024 was $79.1 million, representing a year-over-year growth of approximately 3% [8][19] - Adjusted EPS was a loss of $0.05, an improvement from a loss of $0.09 in the same quarter last year [26] - Gross margin for Q2 FY 2024 was 50.9%, a decrease of 80 basis points compared to the prior year [22][23] Business Line Data and Key Metrics Changes - Med Tech revenue was $25.4 million, a 3.5% year-over-year increase, while Med Device revenue was $53.7 million, growing 2.3% [19] - Mechanical thrombectomy revenue, including AngioVac and AlphaVac, declined 4.7% year-over-year [20] - NanoKnife sales grew approximately 2.8% during the quarter, with total NanoKnife sales up 16.7% year-to-date [12][21] Market Data and Key Metrics Changes - International business grew 12.6% year-over-year, with double-digit growth from both Med Tech and Med Device segments [14] - The U.S. market saw a decline in probe sales for NanoKnife, while capital sales grew robustly by 22.8% [21] Company Strategy and Development Direction - The company is transitioning to a fully outsourced manufacturing model, expected to drive annualized savings of approximately $15 million by FY 2027 [15][16] - Focus remains on portfolio optimization and driving growth in both Med Tech and Med Device businesses [7][18] - Anticipated product launches and regulatory approvals are set to open larger, high-growth markets [17][70] Management's Comments on Operating Environment and Future Outlook - Management acknowledged headwinds in the thrombectomy business but remains optimistic about future growth driven by new product introductions and regulatory approvals [9][37] - The company expects FY 2024 revenue to be in the range of $320 million to $325 million, down from previous guidance [27] - Management emphasized the importance of training and preparing sales teams for upcoming product launches and market expansions [38][39] Other Important Information - Research and development expenses increased to $8.7 million, representing 10.9% of sales, compared to 8.8% of sales a year ago [25] - The company has zero debt on the balance sheet and cash and cash equivalents increased to $60.9 million [26] Q&A Session Summary Question: Will gross margin continue to decrease until the shift to third-party manufacturing is complete? - Management indicated that while there may be fluctuations, the most significant benefits will come at the end of the two-year transition period [33][34] Question: What factors are expected to drive sales increases in thrombectomy? - Management highlighted the breakthrough designation for AngioVac and anticipated FDA approvals as key drivers for future sales growth [36][37] Question: Can you elaborate on the headwinds faced by AngioVac? - Management noted that AngioVac serves a smaller market and emphasized the importance of new sales leadership and training to address challenges [41][42] Question: What improvements are expected with AlphaVac 2? - Management discussed unique design elements of AlphaVac that enhance usability and safety, with pricing positioned competitively in the market [44][46] Question: What is the logistical process for moving to a fully outsourced model? - Management explained that the transition will occur over two years, with established protocols and supplier partnerships already in place [55][56]

AngioDynamics Second Quarter 2024 Earnings Presentation Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | AngioDyn ...

Financial Data and Key Metrics Changes - Revenue for Q1 FY '24 was $78 million, representing a year-over-year growth of approximately 6%, driven by a 13% increase in the MedTech segment [8][20] - Adjusted pro forma EPS was a loss of $0.13, in line with expectations, excluding approximately $700,000 in sales from divested businesses [8][26] - Gross margin for Q1 FY '24 was 50.8%, a decrease of 20 basis points compared to the previous year [23] Business Line Data and Key Metrics Changes - MedTech revenue was $25.9 million, a 13.3% year-over-year increase, while Med Device revenue was $52.1 million, growing 2.3% compared to the first quarter of FY '23 [20] - NanoKnife business grew approximately 36% during the first quarter, with sales of probes growing 35% [11] - Mechanical thrombectomy business, including AngioVac and AlphaVac, declined roughly 6% year-over-year, with AngioVac revenue at $6.3 million, down 7.7% from the prior year [13][21] Market Data and Key Metrics Changes - International businesses grew 26% year-over-year, with strong growth from both MedTech and Med Device segments [12] - U.S. disposable growth for NanoKnife was 28%, while international markets saw a 44% growth [35] Company Strategy and Development Direction - The company aims to address treatment gaps in high-growth markets, focusing on cardiovascular disease and cancer [9] - Plans to submit data to the FDA in Q3 2024 to support an expanded indication for NanoKnife to treat prostate tissue [10] - The company is pursuing plans to gain an indication for Auryon to treat coronary artery disease [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of NanoKnife and the mechanical thrombectomy business, highlighting positive physician feedback [11][38] - The company anticipates FY '24 revenue in the range of $328 million to $333 million, with expected gross margins of 50% to 52% [29][30] Other Important Information - The company revised its annual equity grant practice for non-employee directors, impacting adjusted loss per share for the quarter [26] - Cash and cash equivalents at the end of Q1 FY '24 were $57.6 million, up from $44.6 million at the end of FY '23 [28] Q&A Session Summary Question: Can you break out NanoKnife growth U.S. versus internationally? - U.S. disposable growth was 28%, while international growth was about 44% [35] Question: What is the outlook for AlphaVac growth? - AlphaVac is expected to improve with ongoing clinical studies and design enhancements planned for next year [38] Question: Can you provide an update on Auryon installations? - The company finished the quarter with approximately 415 total lasers in the field, with a focus on driving utilization rather than new system placements [41] Question: What is the sustainability of NanoKnife performance internationally? - The company believes the strong growth is sustainable, supported by training and clinical support for partners [44] Question: How is the company balancing Med Tech growth with cash generation from Med Device? - The company aims to grow its Med Tech segment while maintaining stability from the Med Device segment, which currently provides cash flow [49]